Geron IMerge Phase 3 Presentations At Upcoming ASH Annual Meeting Reinforce Significant Durability And Breadth Of Effect Of Imetelstat In Lower Risk MDS
Portfolio Pulse from Benzinga Newsdesk
Geron Corporation (NASDAQ: GERN) has announced the publication of abstracts from the IMerge Phase 3 clinical trial evaluating its investigational telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes (MDS). The data shows consistently higher transfusion independence (TI) response rates than placebo across different risk groups. Imetelstat is currently under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS.
November 02, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Geron's imetelstat has shown promising results in Phase 3 trials for lower risk MDS, potentially leading to FDA and EMA approval.
The positive results from the Phase 3 trial of imetelstat indicate a high likelihood of approval by the FDA and EMA. This would allow Geron to market the drug for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS, potentially leading to increased revenues for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100